Retention in Methadone Maintenance Is Associated with Reductions in Different HIV Risk Behaviors for Women and Men

Ea, Wells; Da, Calsyn; Ll, Clark; Aj, Saxon; Tr, Jackson

doi:10.3109/00952999609001677

Cited by 45 publications

(16 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Factors independently associated with discontinuing buprenorphine treatment were detectable viral load (OR, 2.7; 95% CI, 1.0-7.7), persistent heroin consumption (OR, 6.1; 95% CI, 1.9-20.0), and female sex (OR, 2.8; 95% CI, 1.0-7.9). These results are partly consistent with those of previous studies of methadone-treated patients [148,149]. Of the 46 patients who discontinued BMT, 25 reported injection drug use at the following visit.…”

Section: Buprenorphine In Hiv-infected Patients: Results From Observasupporting

confidence: 93%

Buprenorphine Use: The International Experience

Carrieri

Amass

Lucas

et al. 2006

Clinical Infectious Diseases

131

100

View full text Add to dashboard Cite

The confluence of the heroin injection epidemic and the human immunodeficiency virus (HIV) infection epidemic has increased the call for expanded access to effective treatments for both conditions. Buprenorphine and methadone are now listed on the World Health Organization's Model Essential Drugs List. In France, which has the most extensive experience, buprenorphine has been associated with a dramatic decrease in deaths due to overdose, and buprenorphine diversion appears to be associated with inadequate dosage, social vulnerability, and prescriptions from multiple providers. Other treatment models (in the United States, Australia, Germany, and Italy) and buprenorphine use in specific populations are also reviewed in the present article. In countries experiencing a dual epidemic of heroin use and HIV infection, such as former states of the Soviet Union and other eastern European and Asian countries, access to buprenorphine and methadone may be one potential tool for reducing the spread of HIV infection among injection drug users and for better engaging them in medical care.

show abstract

Section: Buprenorphine In Hiv-infected Patients: Results From Observasupporting

confidence: 93%

Buprenorphine Use: The International Experience

Carrieri

Amass

Lucas

et al. 2006

Clinical Infectious Diseases

131

100

View full text Add to dashboard Cite

show abstract

“…If methadone daily adherence is achieved each month by the patient, there is up to a 50% discount on their co-pay. Previous research has shown an association between recent HIV risk behaviors and adherence to methadone (Wells, Calsyn, Clark, Saxon, & Jackson, 1996;Wong, Lee, Lim, & Low, 2003). In general, good initial adherence predicts a more favorable lasting substance treatment outcome (Roux et al, 2009;Soyka, Zingg, Koller, & Kuefner, 2008).…”

Section: Aids Care 199mentioning

confidence: 98%

HIV infection as a predictor of methadone maintenance outcomes in Chinese injection drug users

et al. 2011

View full text Add to dashboard Cite

This paper's design is descriptive and correlational based on retrospective self-report survey data collected in Kunming city, China. The study investigated the difference between a group of Chinese HIV positive (N=36) and negative (N=131) opioid dependent adults maintained on methadone treatment. Comparisons were based on their quality of life (QOL), methadone treatment adherence, adverse symptom occurrence related to methadone treatment, and HIV-related behavior changes. No significant differences were found between the two groups in age, methadone maintenance dose, methadone adherence, sex desire, and drug craving level. Participants who were HIV positive reported significantly lower scores on physical health and total health-related qualify of life. They also reported greater engagement in injection related risk behavior before methadone treatment than those who tested HIV negative. For both groups, sexual and injection risk behavior significantly decreased following initiation of methadone treatment. A regression model revealed that those infected with HIV, associated significantly with higher likelihood of reporting constipation and lack of appetite, and higher frequency of reporting abdominal pain and nausea than HIV negative patients. The primary implication of these findings is that HIV positive persons in methadone treatment may require more focused services to meet their special HIV care and substance treatment needs.

show abstract

“…Another review found modest reductions in risky sexual behavior for drug treatment-based HIV prevention programs (Prendergast, Urada, & Podus, 2001). Other studies suggest that the effects of drug treatment may differ by gender (Grella, Annon, & Anglin, 1995;Grella, Etheridge, Joshi, & Anglin, 2000;Hetherington, Harris, Bausell, Kavanagh, & Scott, 1996;Wells, Calsyn, Clark, Saxon, & Jackson, 1996). Furthermore, carefully conducted trials involving intensive long-term detoxification coupled with cognitive therapy (Sees et al, 2000), as well as community-based harm reduction strategies such as needle exchange and bleach distribution (Lurie & Reingold, 1993), have shown improvements in injection-related risk behavior but minimal or no impact on sexual risk practices.…”

Section: Introductionmentioning

confidence: 96%